Regen BioPharma Inc (RGBP)

[OTCShotCaller]

You Nailed it BIG TIME!

Well said and I applaud you for your keen insight.

I can tell you in no uncertain terms as a Clinical Trials Physician the following:

1). The Magnitude of funding Koos is seeking for the Canary Acquisition of Weill-Cornell's technology that makes sense, can ONLY come from a Big Pharma. There are very few sources someone can turn to for funding anywhere close to this amount of money unless it's a major corporation.

2). You're right again that IF this deal doesn't go through, it would result in the perception that Regen and Koos himself are essentially back to square one and that would cast a shadow over the company's market perception and future. It would take A LOT to recover from, so his reputation is definitely on the line like you said.

3). It's very clear that the deal presently on the table for the $50M funding is a Big Pharma which is consistent with Koos 8/27/21 8K where he suggested an Acquisition/Buy Out, only the structuring is "in direct", where the funding is for acquiring the Technology of Weill-Cornell via Regen's new wholly owned subsidiary Canary, and Patent licensing or ownership by the Big Pharma partner, but nevertheless Koos is the principal.

4). It's important to clarify the players and what their roles are. They are #1 Regen; #2 Canary; #3 Weill-Cornell, and #4 an unidentified Big Pharma.

The Big Pharma provides the funding that centers on developing a limited selection of Regen's Innovative Patents, and those Patents are the subject of fast track development into various therapeutics for commercialization via the efforts of Weill-Cornell who holds the technology & expertise for that to happen AND they have a well established history of many Big Pharmas utilizing their services which is similar to the role of a Contract Research Organization (CRO).

Weill-Cornell is functionally playing the role of a CRO as they have the technology, manpower, and capacity to make it all happen, and ALL of this is what Big Pharmas now-a-days hire CROs for because they don't want the labor intensiveness and enormous manpower requirement and cost to bring something like this In-House, and no doubt that was a major deal point between Koos and the Big Pharma presently at the table with him.

No doubt whoever the Big Pharma player is, they wanted a highly qualified source that has the ability to bring Regen's Patents to commercialization which Weill-Cornell has an well established reputation for with many Big Pharmas, and they also have the financial backing of The Bill & Melinda Gates Foundation and no doubt dozens of other financial contributors.

Canary,although they have precision oncology testing platforms that will complement existing cancer genomic testing on patient's tumors allowing physicians to select therapeutics generated through genomic testing down to specific drug combinations, Canary's revolutionary approach to precision oncology is enabled by technology they seek to license from Weill-Cornell as a subsidiary of Regen, and several of Regent's Patents will be included in the drug discovery process upon conversion into a therapeutic.

It should all make sense now! I may be overlooking something but these are the key pieces to the puzzle.

20/20 on Weill-Cornell

https://news.weill.cornell.edu/news/2012/06/weill-cornell-partners-with-pharmaceutical-companies-and-academic-researchers-to-speed-tuberculosis

So for this deal to do down, it will require the $50M from the Big Pharma player presently at the table who no doubt wants a high probability of certainty that the Patents they're acquiring or licensing from Regen included in the $50M funding deal, will enter the Weill-Cornell fast track incubator program for I.P. development into therapeutics via the "perfect marriage" between Canary & Weill-Cornell which the Big Pharma will have a financial stake in, the details of which are unknown at this point.

So essentially it will cost the Big Pharma in bed with Regen far less to fund the development of selected Patents in Regen's portfolio, than to buy Regen outright with all its Patents, and simultaneously acquire the technology from Weill-Cornell for Canary's platforms, which is better for both parties. Regen is then able to continue to license its other Patents with several Big Pharmas while systematically commercializing their Patents via Weill-Cornell's fast track program.

If this deal goes through, what needs to be recognized about it all is it represents a Big Pharma Partnership and whoever that Big Pharma is, at some point they will be licensing and/or claim ownership of those Patents in development at Weill-Cornell.

Like I've said many times before, "Dr. Koos is a genius."

Be well and prosper...